News
Manitoba Health Minister Uzoma Asagwara ordered the province’s health authority, Shared Health, to kill a tongue-in-cheek ...
Breast cancer is the most common cancer in women, with one in eight women being afflicted in their lifetime. It is estimated that more than 30,000 Canadian women were diagnosed with breast cancer in ...
8d
MedPage Today on MSNAlzheimer's Lecanemab Treatment Up to 36 Months Supported by Extension StudySAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...
5don MSN
The president, of his own doing, had single-handedly pushed the global economy to the brink of chaos with new tariffs. The ...
MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025 Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) -- ...
Ajaiya Thomas, a Hope scholar, said she abandoned plans to study veterinary medicine because of LIU’s statement she’d ...
Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver ...
Crackdown’ highlights how drug policy has shaped the toxic drug crisis and what can be done about it. A Tyee Q&A.
Below are the winners along with titles of their projects: Winning Poster Presentation: Blood cytokine profiles in AD and their association with neurodegeneration and clinical severity. The Data ...
Voyager is currently assessing VY7523 in a multiple ascending dose trial in patients with early AD and expects initial tau positron emission tomography (PET) imaging data in the second half of 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results